| Literature DB >> 20109025 |
Maria G Guzman1, Lisset Hermida, Lidice Bernardo, Rosa Ramirez, Gerardo Guillén.
Abstract
A dengue vaccine should induce long-lasting, simultaneous protection to the four dengue viruses while avoiding the immune enhancement of viral infection. Domain III of the dengue envelope protein has been implicated in receptor binding, and is also the target of specific neutralizing antibodies. Domain III has emerged as a promising region for a subunit vaccine candidate. Here, we review the current state of knowledge on vaccine candidates based on domain III. Due to the results obtained concerning the immune response and protection in mice and monkeys, particular attention is paid to the chimeric protein domain III fused to p64k of Neisseria meningitidis.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20109025 DOI: 10.1586/erv.09.139
Source DB: PubMed Journal: Expert Rev Vaccines ISSN: 1476-0584 Impact factor: 5.217